MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.

 

Background

  • Leading commercial cell engineering company providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization

 

Strategy

  • Raise profile as a global leader in the advanced therapies space, and partner-of-choice for cell therapy developer

 

Outcome

  • Strategic communications and IR support provided for MaxCyte since 2015
  • Supported successful listing on AIM in 2016 followed by 2021 Nasdaq IPO raising $201.8 million in gross proceeds
  • Continued engagement with a range of end audiences through compliant media relations and other financial communications activities

$201.8 million

Nasdaq IPO, 2021